{"result": {"id": "86c13794-7034-4c83-a1ae-b418c7e6f44f", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "{\n    \"title\": \"National Medical Products Administration and Pediatric Hypertension Medications\",\n    \"summary\": \"The community centers around the National Medical Products Administration (NMPA), a Chinese regulatory body for drugs, and its approvals of various medications for pediatric hypertension treatment. Key entities include SACUBITRIL/VALSARTAN, LOSARTAN, CAPTOPRIL, and others, all approved by the NMPA for pediatric use. The relationships highlight the NMPA's central role in drug approvals and its connection to other regulatory bodies like the U.S. Food and Drug Administration.\",\n    \"rating\": 7.5,\n    \"rating_explanation\": \"The impact severity rating is high due to the critical nature of pediatric hypertension treatment and the regulatory oversight involved.\",\n    \"findings\": [\n        {\n            \"summary\": \"NMPA's pivotal role in drug approvals\",\n            \"explanation\": \"The National Medical Products Administration (NMPA) is the central entity in this community, responsible for approving a wide range of medications for pediatric hypertension. Its approvals are crucial for the availability and regulation of these drugs in China. The NMPA's relationships with various medications underscore its authority and the trust placed in its regulatory decisions. [Data: Entities (1208), Relationships (1545, 1549, 1540, 1541, 1542,+more)]\"\n        },\n        {\n            \"summary\": \"Diverse range of approved medications\",\n            \"explanation\": \"A diverse range of medications, including SACUBITRIL/VALSARTAN, LOSARTAN, CAPTOPRIL, and others, have been approved by the NMPA for pediatric hypertension treatment. This variety indicates the NMPA's comprehensive approach to addressing pediatric hypertension, ensuring multiple treatment options are available. The approval of these drugs reflects the NMPA's commitment to pediatric healthcare. [Data: Entities (1552, 1145, 1137, 1142, 1506,+more), Relationships (1634, 1549, 1540, 1541, 1542,+more)]\"\n        },\n        {\n            \"summary\": \"Regulatory collaboration with the U.S. FDA\",\n            \"explanation\": \"The NMPA's relationship with the U.S. Food and Drug Administration (FDA) highlights international regulatory collaboration. This connection is significant for global drug approval standards and the exchange of regulatory information, benefiting pediatric hypertension treatment worldwide. [Data: Relationships (1108)]\"\n        },\n        {\n            \"summary\": \"Importance of combination therapies\",\n            \"explanation\": \"The study of combination therapies, such as AMLODIPINE with SACUBITRIL/VALSARTAN, underscores the evolving nature of pediatric hypertension treatment. These combinations are explored to enhance therapeutic outcomes, reflecting the dynamic and innovative approach within this community. [Data: Relationships (2992)]\"\n        },\n        {\n            \"summary\": \"Clinical trials and investigational drugs\",\n            \"explanation\": \"The inclusion of clinical trials like the ASTRONAUT TRIAL, which investigated ALISKIREN, indicates the community's engagement with cutting-edge research to improve pediatric hypertension treatment. Such trials are vital for advancing medical knowledge and treatment options. [Data: Entities (2857), Relationships (2995)]\"\n        }\n    ]\n}", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751560187, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 690, "prompt_tokens": 3202, "total_tokens": 3892, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1472}, "prompt_cache_hit_tokens": 1472, "prompt_cache_miss_tokens": 1730}}, "input": {"messages": [{"content": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\n1552,SACUBITRIL/VALSARTAN,\"A combination drug (ARNI) used for heart failure and hypertension\"\"\",2\n1210,FUROSEMIDE,,3\n1208,NATIONAL MEDICAL PRODUCTS ADMINISTRATION,\"Chinese regulatory body for drugs (mentioned as reference for drug usage guidelines)\"\"\",11\n1145,LOSARTAN,\"**LOSARTAN** is an angiotensin receptor blocker (ARB) medication primarily used for the treatment of hypertension (high blood pressure). It has been approved for use in pediatric patients for managing hypertension. Additionally, LOSARTAN has been studied in combination with other antihypertensive agents to evaluate its efficacy and potential synergistic effects in blood pressure management. As an ARB, it works by blocking the action of angiotensin II, a hormone that constricts blood vessels, thereby helping to lower blood pressure.\",3\n1137,CAPTOPRIL,\"**Captopril** is an angiotensin-converting enzyme inhibitor (ACEI) medication approved for the treatment of hypertension. It is also indicated for use in pediatric patients with hypertension. As an ACE inhibitor, captopril works by relaxing blood vessels, thereby lowering blood pressure and improving cardiovascular function. Its applications include managing high blood pressure in both adults and children.\",2\n1142,FOSINOPRIL,\"Fosinopril is an angiotensin-converting enzyme inhibitor (ACEI) medication primarily used for the treatment of hypertension. It has been approved for use in pediatric patients, making it a viable option for managing high blood pressure in children. As an ACE inhibitor, Fosinopril works by relaxing blood vessels, thereby reducing blood pressure and improving cardiovascular outcomes. Its applications are consistent across both adult and pediatric populations, with a focus on hypertension management.\",2\n1209,U.S. FOOD AND DRUG ADMINISTRATION,\"U.S. regulatory body referenced for drug half-life information\"\"\",1\n1506,AMILORIDE,A diuretic medication approved for pediatric hypertension treatment,1\n1507,CHLORTHALIDONE,A diuretic medication approved for pediatric hypertension treatment,1\n1508,PROPRANOLOL,An adrenergic receptor blocker medication approved for pediatric hypertension treatment,1\n1509,ATENOLOL,An adrenergic receptor blocker medication approved for pediatric hypertension treatment,1\n1510,PRAZOSIN,An adrenergic receptor blocker medication approved for pediatric hypertension treatment,1\n1192,ALISKIREN,\"Aliskiren is a direct renin inhibitor used for treating hypertension with a dosage range of 150-300 mg and a half-life of 40 hours\"\"\",5\n1205,CALCIUM CHANNEL BLOCKERS,\"Class of antihypertensive drugs abbreviated as CCB in the text\"\"\",2\n1128,AMLODIPINE,\"**AMLODIPINE** is a dihydropyridine calcium channel blocker (CCB) primarily used for the treatment of hypertension. It is specifically noted for its effectiveness in managing bevacizumab-induced hypertension. Amlodipine is frequently studied in combination with other medications to enhance therapeutic outcomes. As a calcium channel blocker, it works by inhibiting calcium ion influx into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced blood pressure. Its broad application in hypertension treatment underscores its clinical significance.\",4\n2857,ASTRONAUT TRIAL,A randomized trial evaluating aliskiren's effect on mortality and heart failure readmissions,1\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\n1634,ARNI,SACUBITRIL/VALSARTAN,Sacubitril/valsartan is an ARNI class medication,18\n1545,FUROSEMIDE,NATIONAL MEDICAL PRODUCTS ADMINISTRATION,The NMPA approved furosemide for pediatric use,14\n1549,LOSARTAN,NATIONAL MEDICAL PRODUCTS ADMINISTRATION,The NMPA approved losartan for pediatric use,14\n1540,CAPTOPRIL,NATIONAL MEDICAL PRODUCTS ADMINISTRATION,The NMPA approved captopril for pediatric use,13\n1541,FOSINOPRIL,NATIONAL MEDICAL PRODUCTS ADMINISTRATION,The NMPA approved fosinopril for pediatric use,13\n1108,NATIONAL MEDICAL PRODUCTS ADMINISTRATION,U.S. FOOD AND DRUG ADMINISTRATION,Both are drug regulatory agencies referenced in the document,12\n1542,AMILORIDE,NATIONAL MEDICAL PRODUCTS ADMINISTRATION,The NMPA approved amiloride for pediatric use,12\n1543,CHLORTHALIDONE,NATIONAL MEDICAL PRODUCTS ADMINISTRATION,The NMPA approved chlorthalidone for pediatric use,12\n1546,PROPRANOLOL,NATIONAL MEDICAL PRODUCTS ADMINISTRATION,The NMPA approved propranolol for pediatric use,12\n1547,ATENOLOL,NATIONAL MEDICAL PRODUCTS ADMINISTRATION,The NMPA approved atenolol for pediatric use,12\n1548,PRAZOSIN,NATIONAL MEDICAL PRODUCTS ADMINISTRATION,The NMPA approved prazosin for pediatric use,12\n1098,ALISKIREN,CALCIUM CHANNEL BLOCKERS,Both are antihypertensive agents mentioned in the document,7\n2992,AMLODIPINE,SACUBITRIL/VALSARTAN,Studied in combination for treating systolic hypertension in Asian patients,6\n2995,ALISKIREN,ASTRONAUT TRIAL,Aliskiren was the investigational drug in this heart failure outcomes trial,6\n1106,CALCIUM CHANNEL BLOCKERS,FUROSEMIDE,Both are classes of antihypertensive medications mentioned in the same document,5\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 2000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0, "response_format": {"type": "json_object"}}}, "key": "chat_create_community_report_f9fbb63c7bb7496ea6fd85eeec04e6a0a6a2b09cd53ebd411d24ae2b351c1107_v2"}